Magery Satish, MD
Child & Adolescent Psychiatry · Setauket, NYNPI 1730228800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations.
Across 137 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
- Lundbeck LLC$493
- Alkermes, Inc.$483
- Otsuka America Pharmaceutical, Inc.$328
- Takeda Pharmaceuticals U.S.A., Inc.$207
- E.r. Squibb & Sons, L.L.C.$153
- plus $770 from 11 others
What the payments were for
- Food & beverage$2,93099%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,962 in reported general payments places this provider in the 85th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 123 | $184,752 |
| VraylarCariprazine Hcl | 106 | $157,285 |
| CaplytaLumateperone Tosylate | 33 | $57,162 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $45,105 |
| TrintellixVortioxetine Hydrobromide | 55 | $30,096 |
| ZyprexaOlanzapine | 29 | $26,951 |
| Divalproex Sodium ErDivalproex Sodium | 274 | $24,350 |
| Lurasidone Hcl | 68 | $16,803 |
| Chlorpromazine Hcl | 48 | $15,294 |
| Quetiapine Fumarate | 371 | $13,252 |
| Aripiprazole | 303 | $11,747 |
| Olanzapine | 348 | $11,293 |
| Clozapine | 52 | $8,791 |
| Lamotrigine | 450 | $7,961 |
| Divalproex Sodium | 213 | $7,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $328 | $184,752123 claims |
| AbbVieVraylar | $98 | $157,285106 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $529 | $57,16233 claims |
| Alkermes, Inc.Lybalvi | $483 | $45,10527 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $207 | $35,06868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in Setauket
- Debra EmerySetauket$3K
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Parinda ParikhWhite Plains$185K
- Jeffrey NewcornNew York$165K
- John MarinoCanandaigua$70K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Vijay PampanaMiddletown$19K
- Marc ReitmanHuntington$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.